Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAFAEL ABREU

Allopathic & Osteopathic Physicians Family Medicine

NPI
1265769822
CMS profile
12277
Location
HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$165.04

10 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $165.04 10

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAFAEL ABREU

NPI 1265769822 · CMS profile ID 12277

Allopathic & Osteopathic Physicians / Family Medicine

HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1265769822?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAFAEL ABREU, NPI 1265769822, CMS profile ID 12277. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265769822?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). RAFAEL ABREU, NPI 1265769822, CMS profile ID 12277. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265769822?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
RAFAEL ABREU, NPI 1265769822, CMS profile ID 12277, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1265769822?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

10 matching records · $165.04 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 10 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–10 of 10.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $17.7711/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749559761 CMS
Teva Pharmaceuticals USA, Inc. $18.4810/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749559725 CMS
Daiichi Sankyo Inc. $13.0109/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739499107 CMS
Teva Pharmaceuticals USA, Inc. $18.4809/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749559771 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.2907/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737478745 CMS
Janssen Pharmaceuticals, Inc $17.4807/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719360477 CMS
Teva Pharmaceuticals USA, Inc. $15.7403/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749516095 CMS
Janssen Pharmaceuticals, Inc $13.2802/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719360473 CMS
Teva Pharmaceuticals USA, Inc. $15.7402/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749491559 CMS
Janssen Pharmaceuticals, Inc $14.7701/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719360475 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $603.64 19
PY2020 $165.04 10
PY2021 $374.56 15
PY2022 $172.11 5
PY2023 $340.05 13
PY2024 $765.65 18
PY2025 $438.74 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $125,091.79 77
PY2024 Principal investigator $287,947.99 115
PY2023 Recipient $300.00 1
PY2023 Principal investigator $3,667.40 2
PY2022 Recipient $300.00 1
PY2022 Principal investigator $49,466.88 5
PY2021 Recipient $20,166.46 2
PY2021 Principal investigator $24,617.76 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

115 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bausch Health US, LLC $422.00 12/06/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685452
Principal investigator 1 Bausch Health US, LLC $1,880.00 12/06/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685461
Principal investigator 1 Bausch Health US, LLC $1,880.00 12/06/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685470
Principal investigator 1 Bausch Health US, LLC $1,880.00 12/06/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685479
Principal investigator 1 Bausch Health US, LLC $1,880.00 12/06/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685492
Principal investigator 1 Bausch Health US, LLC $422.00 12/06/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685501
Principal investigator 1 Bausch Health US, LLC $422.00 12/06/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685505
Principal investigator 1 Bausch Health US, LLC $422.00 12/06/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685510
Principal investigator 1 Bausch Health US, LLC $1,880.00 12/06/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685514
Principal investigator 1 Bausch Health US, LLC $1,779.00 12/06/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685532
Principal investigator 1 Bausch Health US, LLC $1,722.00 10/25/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685457
Principal investigator 1 Bausch Health US, LLC $1,722.00 10/25/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685465
Principal investigator 1 Bausch Health US, LLC $1,722.00 10/25/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685474
Principal investigator 1 Bausch Health US, LLC $422.00 10/25/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685483
Principal investigator 1 Bausch Health US, LLC $1,722.00 10/25/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685487
Principal investigator 1 Bausch Health US, LLC $422.00 10/25/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685496
Principal investigator 1 Bausch Health US, LLC $422.00 10/25/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685519
Principal investigator 1 Bausch Health US, LLC $422.00 10/25/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685523
Principal investigator 1 Bausch Health US, LLC $996.00 10/23/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685528
Principal investigator 1 Bausch Health US, LLC $1,722.00 09/25/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685329
Principal investigator 1 Bausch Health US, LLC $1,722.00 09/25/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685333
Principal investigator 1 Bausch Health US, LLC $1,722.00 09/25/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685382
Principal investigator 1 Bausch Health US, LLC $422.00 09/25/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685386
Principal investigator 1 Bausch Health US, LLC $422.00 09/25/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685395
Principal investigator 1 Bausch Health US, LLC $422.00 09/25/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685417
Principal investigator 1 Bausch Health US, LLC $1,880.00 09/25/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685443
Principal investigator 1 Bausch Health US, LLC $422.00 09/04/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685338
Principal investigator 1 Bausch Health US, LLC $1,388.00 09/04/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685342
Principal investigator 1 Bausch Health US, LLC $1,779.00 09/04/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685351
Principal investigator 1 Bausch Health US, LLC $1,162.00 09/04/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685360
Principal investigator 1 Bausch Health US, LLC $1,880.00 09/04/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685364
Principal investigator 1 Bausch Health US, LLC $422.00 09/04/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685391
Principal investigator 1 Bausch Health US, LLC $422.00 09/04/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685404
Principal investigator 1 Bausch Health US, LLC $422.00 09/04/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685426
Principal investigator 1 Bausch Health US, LLC $1,779.00 09/04/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685435
Principal investigator 1 Bausch Health US, LLC $830.00 08/23/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685377
Principal investigator 1 AstraZeneca Pharmaceuticals LP $86,659.99 08/21/2024 Non-covered Recipient Entity
SUPERIOR ASSOCIATES IN RESEARCH LLC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1110844432
Principal investigator 1 Bausch Health US, LLC $422.00 08/02/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685355
Principal investigator 1 Bausch Health US, LLC $1,779.00 08/02/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685373
Principal investigator 1 Bausch Health US, LLC $422.00 08/02/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685400
Principal investigator 1 Bausch Health US, LLC $1,779.00 08/02/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685408
Principal investigator 1 Bausch Health US, LLC $1,779.00 08/02/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685421
Principal investigator 1 Bausch Health US, LLC $1,722.00 08/02/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685430
Principal investigator 1 Bausch Health US, LLC $422.00 08/02/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685439
Principal investigator 1 Bausch Health US, LLC $422.00 07/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685347
Principal investigator 1 Bausch Health US, LLC $422.00 07/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685368
Principal investigator 1 Bausch Health US, LLC $422.00 07/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685413
Principal investigator 1 Bausch Health US, LLC $1,722.00 07/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685448
Principal investigator 1 Bausch Health US, LLC $1,779.00 06/24/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685178
Principal investigator 1 Bausch Health US, LLC $1,722.00 06/24/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685201
Principal investigator 1 Bausch Health US, LLC $422.00 06/24/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685223
Principal investigator 1 Bausch Health US, LLC $1,388.00 06/24/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685236
Principal investigator 1 Bausch Health US, LLC $1,722.00 06/24/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685284
Principal investigator 1 Bausch Health US, LLC $7,138.00 06/21/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685156
Principal investigator 1 Bausch Health US, LLC $996.00 06/21/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685297
Principal investigator 1 Bausch Health US, LLC $1,722.00 06/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685161
Principal investigator 1 Bausch Health US, LLC $1,779.00 06/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685165
Principal investigator 1 Bausch Health US, LLC $422.00 06/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685174
Principal investigator 1 Bausch Health US, LLC $1,388.00 06/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685187
Principal investigator 1 Bausch Health US, LLC $1,779.00 06/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685196
Principal investigator 1 Bausch Health US, LLC $1,779.00 06/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685205
Principal investigator 1 Bausch Health US, LLC $1,779.00 06/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685209
Principal investigator 1 Bausch Health US, LLC $1,779.00 06/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685218
Principal investigator 1 Bausch Health US, LLC $1,779.00 06/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685227
Principal investigator 1 Bausch Health US, LLC $1,722.00 06/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685254
Principal investigator 1 Bausch Health US, LLC $422.00 06/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685259
Principal investigator 1 Bausch Health US, LLC $1,388.00 06/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685263
Principal investigator 1 Bausch Health US, LLC $1,779.00 06/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685267
Principal investigator 1 Bausch Health US, LLC $1,722.00 06/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685271
Principal investigator 1 Bausch Health US, LLC $1,388.00 06/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685289
Principal investigator 1 Bausch Health US, LLC $1,388.00 06/05/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685293
Principal investigator 1 Bausch Health US, LLC $1,823.00 05/01/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685152
Principal investigator 1 Bausch Health US, LLC $3,335.00 05/01/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685183
Principal investigator 1 Bausch Health US, LLC $1,722.00 05/01/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685214
Principal investigator 1 Bausch Health US, LLC $1,823.00 05/01/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685231
Principal investigator 1 Bausch Health US, LLC $422.00 05/01/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685245
Principal investigator 1 Bausch Health US, LLC $422.00 05/01/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685250
Principal investigator 1 Bausch Health US, LLC $1,823.00 05/01/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685280
Principal investigator 1 Bausch Health US, LLC $1,823.00 05/01/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685302
Principal investigator 1 Bausch Health US, LLC $3,335.00 05/01/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685306
Principal investigator 1 Bausch Health US, LLC $1,823.00 05/01/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685315
Principal investigator 1 Bausch Health US, LLC $3,335.00 05/01/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685320
Principal investigator 1 Bausch Health US, LLC $3,335.00 05/01/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685324
Principal investigator 1 Bausch Health US, LLC $3,335.00 04/01/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685169
Principal investigator 1 Bausch Health US, LLC $2,004.00 04/01/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685192
Principal investigator 1 Bausch Health US, LLC $3,335.00 04/01/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685241
Principal investigator 1 Bausch Health US, LLC $2,004.00 04/01/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685276
Principal investigator 1 Bausch Health US, LLC $1,779.00 04/01/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685311
Principal investigator 1 Bausch Health US, LLC $3,335.00 03/22/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685059
Principal investigator 1 Bausch Health US, LLC $2,004.00 03/22/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685076
Principal investigator 1 Bausch Health US, LLC $1,722.00 03/22/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685099
Principal investigator 1 Bausch Health US, LLC $2,004.00 03/22/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685121
Principal investigator 1 Bausch Health US, LLC $1,722.00 03/22/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685125
Principal investigator 1 Bausch Health US, LLC $3,335.00 03/22/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685130
Principal investigator 1 Bausch Health US, LLC $2,004.00 03/22/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685134
Principal investigator 1 Bausch Health US, LLC $3,335.00 03/22/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685138
Principal investigator 1 Bausch Health US, LLC $1,823.00 03/06/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685033
Principal investigator 1 Bausch Health US, LLC $1,779.00 03/06/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685063
Principal investigator 1 Bausch Health US, LLC $3,335.00 03/06/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685090
Principal investigator 1 Bausch Health US, LLC $1,779.00 03/06/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685094
Principal investigator 1 Bausch Health US, LLC $2,578.00 02/07/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685050
Principal investigator 1 Bausch Health US, LLC $2,596.00 02/07/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685068
Principal investigator 1 Bausch Health US, LLC $9,986.00 02/07/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685112
Principal investigator 1 Bausch Health US, LLC $1,000.00 02/07/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685116
Principal investigator 1 Bausch Health US, LLC $2,004.00 02/02/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685037
Principal investigator 1 Bausch Health US, LLC $3,335.00 02/02/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685042
Principal investigator 1 Bausch Health US, LLC $1,823.00 02/02/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685046
Principal investigator 1 Bausch Health US, LLC $3,335.00 02/02/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685055
Principal investigator 1 Bausch Health US, LLC $3,335.00 02/02/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685072
Principal investigator 1 Bausch Health US, LLC $3,335.00 02/02/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685081
Principal investigator 1 Bausch Health US, LLC $3,335.00 02/02/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685085
Principal investigator 1 Bausch Health US, LLC $1,388.00 02/02/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685103
Principal investigator 1 Bausch Health US, LLC $2,004.00 02/02/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685107
Principal investigator 1 Bausch Health US, LLC $2,004.00 02/02/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685143
Principal investigator 1 Bausch Health US, LLC $1,823.00 02/02/2024 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151685147